Press Release Archive

Our Company April 14, 2021

Johnson & Johnson Statement on CDC Advisory Committee Meeting on Company COVID-19 Vaccine

Johnson & Johnson Statement on CDC Advisory Committee Meeting on Company COVID-19 Vaccine

Our Company April 13, 2021

Johnson & Johnson Statement on COVID-19 Vaccine (Updated)

Johnson & Johnson Statement on COVID-19 Vaccine (Updated)

Our Company April 12, 2021

Johnson & Johnson to Participate in the BofA Securities Virtual 2021 Healthcare Conference

Johnson & Johnson to Participate in the BofA Securities Virtual 2021 Healthcare Conference

New Brunswick, NJ (April 12^th, 2021) -- Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Virtual 2021 Healthcare Conference on Tuesday, May 11^th. Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time).
This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com.

A webcast and podcast replay will be available approximately 48 hours after the live webcast.

###

Innovation April 06, 2021

New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients

New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients

Data from the SPHERE Registry published in the Journal of Heart and Lung Transplantation

Our Company April 03, 2021

Johnson & Johnson Statement on U.S. COVID-19 Vaccine Manufacturing (Updated)

Johnson & Johnson Statement on U.S. COVID-19 Vaccine Manufacturing (Updated)

Our Company April 02, 2021

Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents

Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents

Expansion of ongoing trial to include adolescents 12-17 years of age reflects commitment to people of all ages affected by pandemic

Our Company March 31, 2021

Johnson & Johnson Statement on U.S. COVID-19 Vaccine Manufacturing

Johnson & Johnson Statement on U.S. COVID-19 Vaccine Manufacturing

Our Company March 29, 2021

Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company’s COVID-19 Vaccine Candidate

Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company’s COVID-19 Vaccine Candidate

Up to 400 million doses of the Company’s single-shot vaccine candidate will be made available to African Union member states

Availability of the vaccine is subject to national regulatory approvals

Data have demonstrated vaccine candidate protects against COVID-19 related hospitalization and death in broad geographic regions, including those with variants of significant concern

Innovation March 26, 2021

Janssen Receives Positive CHMP Opinion for PONVORY™ (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features

Janssen Receives Positive CHMP Opinion for PONVORY™ (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features

Positive opinion is based on the pivotal Phase 3 OPTIMUM study evaluating the efficacy and safety of ponesimod vs. teriflunomide, an active comparator and oral standard of care treatment in adult patients with relapsing multiple sclerosis^[1]

The OPTIMUM study demonstrated a statistically significant reduction in relapses and number of inflammatory lesions compared with teriflunomide^[2]

Our Company March 24, 2021

Johnson & Johnson Announces Five Initiatives to Help Find the ‘Missing Millions’ of Undiagnosed People Living with Tuberculosis

Johnson & Johnson Announces Five Initiatives to Help Find the ‘Missing Millions’ of Undiagnosed People Living with Tuberculosis

Three out of 10 people with TB go undiagnosed and untreated, a situation exacerbated by health disruptions caused by the COVID-19 pandemic

Collaborating with the Global Fund, USAID, PATH and others will help more people access TB care

These initiatives build on Johnson & Johnson’s longstanding commitment to tackling TB and addressing health inequity in high-burden countries

Topic

Date